BriaCell Therapeutics (TSE:BCT) Trading Down 20.9% – Here’s What Happened

BriaCell Therapeutics Corp. (TSE:BCT)’s share price dropped 20.9% on Friday . The stock traded as low as C$4.27 and last traded at C$4.39. Approximately 93,500 shares changed hands during mid-day trading, an increase of 283% from the average daily volume of 24,408 shares. The stock had previously closed at C$5.55.

BriaCell Therapeutics Price Performance

The business has a fifty day moving average of C$5.69 and a 200-day moving average of C$8.73. The stock has a market capitalization of C$30.67 million, a price-to-earnings ratio of -0.29 and a beta of 1.95.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.